Raghuram Selvaraju

Inovio Pharmaceuticals Inc (NASDAQ: INO), which has had a legal tussle with its South Korean CDMO, announced Tuesday an agreement with Thermo Fisher Scientific Inc. (NYSE: TMO) to manufacture Inovio's DNA COVID-19 vaccine. The Inovio Analyst: H.C. Wainwright analyst Raghuram Selvaraju...

Inovio Pharmaceuticals Inc (NASDAQ: INO) shares have rallied strongly in late June, moving from $14.27 on June 19 to $31.25 on July 25, translating to a stellar gain of about 110%. Much of the upside stemmed from a $71-million DoD contract award for its COVID-19 vaccine delivery device. The...

The binary event that was scheduled for last week panned out in favor of Evoke Pharma Inc (NASDAQ: EVOK). What Happened: The Solana Beach, California-based specialty pharma company said the FDA gave its nod for its Gimoti nasal spray that would allow the company to commercially market it in the U.S...

Sorrento Therapeutics Inc (NASDAQ: SRNE) shares were headed higher Thursday following an announcement concerning its antibody test kit for SARS-CoV-2, the virus that causes COVID-19. What Happened: Sorrento said it has filed for an Emergency Use Authorization for its in vitro diagnostic test kit...

A day after short seller Citron Research slammed Inovio Pharmaceuticals Inc (NASDAQ: INO), sell-side analysts lined up behind the company.  Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus...

Sorrento Therapeutics Inc (NASDAQ: SRNE) shares spiked 158% Friday after the company disclosed that it has identified an antibody that demonstrated 100% inhibition of SARS-CoV-2 virus infection. The Sorrento Analyst H.C. Wainwright analyst Raghuram Selvaraju has a Buy rating on Sorrento with a $...

Despite Inovio Pharmaceuticals Inc's (NASDAQ: INO) first-quarter miss Monday, the sell-side remains largely upbeat on company, which is developing a coronavirus vaccine candidate.  The Inovio Analysts Stifel analyst Stephen Wiley maintained a Buy rating and $19 price target for Inovio...

Coronavirus vaccine play Inovio Pharmaceuticals Inc (NASDAQ: INO) announced the completion of enrollment in the Phase 1 trial of its COVID-19 DNA vaccine INO-4800 and positive Phase 1/2a data for its MERS coronavirus vaccine INO-4700 on Tuesday. The Inovio Analysts Cantor Fitzgerald analyst...

Immunomedics, Inc. (NASDAQ: IMMU) is a biopharma company focusing on the development of antibody-drug conjugates, or ADCs. The Morris Plains, New Jersey-based company was founded in 1982 and has yet to market a commercial product.  Its investigational therapies include ADCs that are...

The five-day European Society of Medical Oncology, or ESMO, Congress 2019 is set to conclude Tuesday in Barcelona, Spain. Touted as a congress where the exchange of translational cancer science of excellence takes place, the gathering brings together pharma and biotech companies focused...

Stemline Therapeutics Inc (NASDAQ: STML) has received FDA approved for Elzonris ahead of the Feb. 21 PDUFA date. The approval coming in two months early highlights “the urgent need” in the indication, according to H.C. Wainwright. The Analyst Analyst Raghuram Selvaraju initiated...

Aerpio Pharmaceuticals Inc (OTC: ARPO), an OTC-listed company specializing in drug development for ocular diseases, earned a bullish review Wednesday. The interest in the stock can only go higher, as the company seeks to up-list the shares on the Nasdaq in the coming months, according to H.C....

Analysts at H.C. Wainwright initiated coverage Thursday on two pharmaceutical companies developing cancer-related vaccines and treatments. Interpace: Efficient Diagnosis, Expanding Reimbursement Coverage Analyst Raghuram Selvaraju initiated coverage on Interpace Diagnostics Group, Inc. (NASDAQ:...

HTG Molecular Diagnostics Inc (NASDAQ: HTGM), a provider of instruments, reagents and services for molecular profiling, announced Tuesday a new master collaboration agreement with Germany's Merck KGaA(ADR) (OTC: MKKGY).  The agreement complements HTG Molecular's previously...

Amid “overstated” legal issues and in the aftermath of natural disaster, Valeant Pharmaceuticals Intl Inc (NYSE: VRX) may profit from a positive catalyst this week, according to H.C. Wainwright & Co. Analyst Raghuram Selvaraju reiterated a Neutral rating on the stock with a $17...